Chercheuse ou chercheur

• Formation complémentaire en épidemiologie hospitalière et infections reliées à la fibrose kystique, The Hospital for Sick Children, University of Toronto, 2020
• Certificat, Centre for Quality Improvement and Patient Safety, University of Toronto, 2020
• Maitrise en Sciences, Clinical Epidemiology and Healthcare Research, Institute of Health Policy, Management and Evaluation, Université de Toronto, 2019
• Résidence en maladies infectieuses pédiatriques, Université de Toronto, The Hospital for Sick Children, 2017
• Résidence en pédiatrie, Université de Montréal, 2015
• MDCM, Université McGill, 2012

Sommaire de carrière

Dr. Ana C. Blanchard est pédiatre infectiologue et conseillère médicale en prévention des infections, au CHU Sainte-Justine. Suite à sa formation en maladies infectieuses pédiatriques à SickKids, elle a complété une formation complémentaire de recherche en épidémiologie hospitalière et traitement des infections liées à la fibrose kystique à l’Université de Toronto. Elle a également obtenu une maîtrise avec thèse en épidémiologie clinique.

Elle développe une carrière de recherche dans le domaine des infections chez les populations à risque, en particulier les enfants atteints de fibrose kystique. Elle est également intéressée par les infections nosocomiales et la résistance antimicrobienne.

Prix et distinctions

• Robert Remis Award, University of Toronto, Dalla Lana School of Public Health, 2020
• Invited Chair Travel Grant, Cystic Fibrosis Foundation, North American Cystic Fibrosis Conference, 2019
• Research Travel Grant, University of Toronto, School of Graduate Studies, 2019
• Trainee Travel Grant, Society for Hospital Epidemiology of America Spring Meeting, 2019
• Jonathan Freeman Scholarship Awardee, Society for Hospital Epidemiology of America, 2019
• Trainee Travel Grant, Infectious Diseases Society of America, IDweek, 2018
• Trainee Travel Grant, Cystic Fibrosis Foundation, North American Cystic Fibrosis Conference, 2018
• Research Fellowship Award, Fonds de Recherche du Québec Santé, 2018
• Jennifer and Robert Sturgess Research Fellow Awardee, Cystic Fibrosis Canada, 2018
• Research Fellowship Award, Cystic Fibrosis Canada, 2018
• Trainee Travel Grant, Cystic Fibrosis Foundation, North American Cystic Fibrosis Conference, 2017
• Clinical Fellowship Award, Cystic Fibrosis Canada, 2017
• Teaching Excellence Award, The Hospital for Sick Children, University of Toronto, 2017
• Trainee Travel Grant, Cystic Fibrosis Foundation, North American Cystic Fibrosis Conference, 2016
• Trainee Travel Grant, Infectious Diseases Society of America, IDWeek, 2014

Publications

• Stapleton PJ, Izydorczyk C, Clark S, Blanchard AC, Wang PW, Yau Y, Waters V, Guttman DS. (2020). Pseudomonas aeruginosa strain sharing in early infection among children with cystic fibrosis. Clinical Infectious Diseases 2020 June 16: ciaa788. Online ahead of print: 1-27
• Blanchard AC, Tang L, Tadros M, Muller MP, Spilker T, Waters V, LiPumma JJ, Tullis E. (2020). Burkholderia cenocepacia ET12 transmission in adults with cystic fibrosis. Thorax. 75(1): 88-90.
• Blanchard AC, Waters V. (2019). Microbiology of CF airways disease. Cystic fibrosis: advances in understanding and treatment. Semin in Respir Crit Care Med.40(6):727-36.
• Blanchard AC, Rooney AM, Yau Y, Zhang Y, Stapleton PJ, Horton E, Klingel M, Stanojevic S, Ratjen F,Coburn B, Waters V. (2018). Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.J Cyst Fibros.17(6): 723-8.
• Kinlin LM, Blanchard AC, Silver S, Morris SK. Scurvy as mimicker of osteomyelitis in a child with autism spectrum disorder. Int J Infect Dis 2018; 69: 99-102.
• Blanchard AC., Fortin E., Laferrière C., Goyer I., Moussa A., Autmizguine J., Quach C. (2017). Comparative effectiveness of linezolid versus vancomycin as definitive antibiotic therapy for heterogeneous vancomycin-intermediate coagulase negative staphylococcal central-line associated blood infections in a neonatal intensive care unit. J Antimicrob Chemother.72(6): 1812-7.
• Blanchard AC., Horton E., Stanojevic S., Taylor L., Waters V., Ratjen F. (2017). Effectiveness of a stepwise pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros.16(3): 395-400.
• Chong J, Lévesque S, Blanchard AC, Laferrière C, Quach C. Central line associated bloodstream infections in the NICU: does heterogeneous vancomycin-intermediate resistance of coagulase negative staphylococcus matter? JAMMI 2017; 2 (1): 47-55
• Chong J., Quach C., Blanchard AC., Guillaume Poliquin P., Golding G., Laferrière C., Lévesque S. (2016). Molecular epidemiology of vancomycin-intermediate heteroresistant coagulase-negative staphylococcus outbreak in the neonatal intensive care unit. Antimicrob Agents Chemother.60(10): 5673-81.
• Blanchard AC, Quach C, Autmizguine J. (2015). Staphylococcal infections in infants: updates and current challenges. Neonatal-Perinatal Infections: An Update. Clin Perinatol.42(1): 119-32.
• Mohamed I, Blanchard AC, Delvin E, Cousineau J, Carceller A. Plotting transcutaneous bilirubin measurements on specific transcutaneous nomogram results in better prediction of significant hyperbilirubinemia in healthy term and near-term newborns: a Pilot Study. Neonatology 2014; 105: 306-11
• Blanchard AC, Fortin E, Rocher I, Moore DL, Frenette C, Tremblay C, Quach C.  Central-line-associated bloodstream infection in neonatal intensive care units. Infect Control Hosp Epidemiol. 2013; Nov; 34 (11): 1167-73